All Interventions

    NLRP3 Inflammasome Inhibition

    Emerging
    Inflammaging & Innate Immunity

    An investigational drug class that blocks assembly or activation of the NLRP3 inflammasome, the innate-immune sensor upstream of IL-1-beta and IL-18 release. NLRP3 activity rises with age and adiposity and is a leading candidate mechanism for the chronic low-grade inflammation (inflammaging) that tracks with cardiovascular, metabolic and neurodegenerative risk. Small-molecule oral inhibitors are now in Phase 2.

    Evidence Summary

    4
    / 10Score
    Emerging (Phase 2 fully enrolled; topline hsCRP data expected Q4 2026; no published efficacy data)
    Emerging Evidence

    MIXED EVIDENCE MATURITY - read the categories separately. (1) BIOLOGICAL RATIONALE: strong and peer-reviewed. The IL-1-beta axis is a validated cardiovascular target - CANTOS showed canakinumab reduced recurrent cardiovascular events independent of lipid lowering, at the cost of increased fatal infection. NLRP3 sits directly upstream. (2) ADJACENT MECHANISTIC WORK: peer-reviewed and supportive of receptor-level inflammaging targeting generally. Wang et al. (Nature Aging, 11 August 2026) showed TNFR1 signalling links systemic inflammation to impaired fatty acid oxidation and intestinal stem cell aging in mice, with the phenotype transferable via shared circulation - a different receptor, but the same thesis that inflammaging is resolvable into specific druggable nodes rather than a diffuse phenotype. (3) CLINICAL DATA FOR SPECIFIC AGENTS: early and sponsor-reported only. BioAge Labs dosed the first participant in QUELL-CV, a Phase 2 proof-of-concept of the oral brain-penetrant NLRP3 inhibitor BGE-102, in June 2026; the study characterises hsCRP dose-response across three once-daily doses in participants with obesity, elevated systemic inflammation and additional cardiovascular risk. Phase 1 hsCRP reductions described as potentially best-in-class are company statements from an April 2026 press release, not a peer-reviewed dataset. Topline Phase 2 data are guided for H2 2026. Nothing here demonstrates clinical benefit; hsCRP is a surrogate. UPDATE (November 5, 2026): The first controlled human readout on an oral NLRP3 inhibitor is now imminent. In its Q3 2026 results (November 5, 2026), BioAge Labs reported that QUELL-CV - a randomized, double-blind, placebo-controlled Phase 2 dose-ranging study of the oral NLRP3 inhibitor BGE-102 in adults with obesity and elevated baseline inflammation - has completed enrollment at approximately 160 participants across 30, 60 and 90 mg once-daily arms versus placebo, with the primary endpoint being percent change in hsCRP over 12 weeks and topline data guided for Q4 2026. From its full Phase 1 dataset the company reported up to 98% suppression of IL-1-beta at trough (ex vivo whole-blood assay) and median hsCRP reductions of about 86% at 60-120 mg once daily, with a well-tolerated profile and notable brain and ocular penetration; a sibling Phase 2 (QUELL-DME, diabetic macular edema) dosed its first participant in September 2026 with topline expected in H2 2027. These Phase 1 figures remain company-reported rather than peer-reviewed, and hsCRP and IL-1-beta are surrogate biomarkers - QUELL-CV is designed to characterize dose-response, not clinical outcomes, so even a positive read will not establish event reduction. Separately, a mechanistic caution: Science Advances 2026 (Muela-Zarzuela, Cordero et al.) found that NLRP3 haploinsufficiency in mice triggered compensatory NLRP1 overexpression and a hybrid NLRP1-NLRP3 inflammasome that ACCELERATED aging (median survival 30 months in wild-type versus 23 months in Nlrp3-heterozygous mice, partially rescued to 28 months when Nlrp1 was also reduced). Constitutive partial loss of NLRP3 is therefore not automatically beneficial; this is a genetic model distinct from reversible, dose-titrated pharmacologic inhibition, but it argues against a naive less-NLRP3-is-better assumption and for careful dose and context selection.

    Evidence Scale

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    AnecdotalStrong RCT

    Mechanism of Action

    NLRP3 assembles with ASC and caspase-1 in response to a broad range of danger signals - cholesterol crystals, extracellular ATP, mitochondrial DNA, urate, and cytosolic DNA sensed via cGAS-STING crosstalk. Assembly triggers caspase-1-mediated maturation and release of IL-1-beta and IL-18 and can drive gasdermin-D pyroptosis. This axis is mechanistically upstream of hsCRP and of the residual inflammatory risk that CANTOS demonstrated is modifiable with canakinumab (anti-IL-1-beta) in secondary cardiovascular prevention. Oral small-molecule NLRP3 inhibitors aim to hit the same axis proximally, orally, and at lower cost than a biologic. Brain-penetrant candidates additionally target microglial inflammasome activity relevant to neurodegeneration.

    Who Is This For?

    No candidates outside a registered clinical trial. Patients with obesity, elevated hsCRP despite optimised lipids, and additional cardiovascular risk factors are the population these trials are enrolling and may be appropriate for trial referral.

    Protocol & Dosing

    Dose

    Not applicable - investigational. Do not extrapolate from press-release dose levels.

    Frequency

    Not applicable (investigational)

    Duration

    Not applicable (investigational)

    Protocol Summary

    No approved NLRP3 inhibitor exists for any indication. There is no protocol to offer. Patients with elevated hsCRP and residual inflammatory risk are managed with established measures: lipid lowering to target, weight and visceral adiposity reduction, glycaemic control, sleep and exercise, smoking cessation, and where appropriate colchicine, which has cardiovascular outcome data in chronic coronary disease.

    Latest Evidence

    Nov 2026: first oral NLRP3 inhibitor nears its first controlled readout

    In its Q3 2026 update (November 5, 2026), BioAge Labs reported that QUELL-CV — a randomized, placebo-controlled Phase 2 study of the oral NLRP3 inhibitor BGE-102 in adults with obesity and elevated inflammation — has completed enrollment (about 160 participants, 30/60/90 mg once daily), with an hsCRP primary endpoint over 12 weeks and topline data expected in Q4 2026. From its full Phase 1 dataset the company reported up to 98% suppression of IL-1β at trough and median hsCRP reductions near 86% at 60–120 mg once daily. These Phase 1 figures are company-reported, not peer-reviewed, and hsCRP and IL-1β are surrogate biomarkers, not clinical outcomes.

    The human proof-of-concept for this axis remains CANTOS, where the IL-1β antibody canakinumab (downstream of NLRP3) lowered hsCRP dose-dependently but cut cardiovascular events at only one dose and raised fatal infections. A 2026 Science Advances study is a further caution: in mice, partial genetic loss of NLRP3 triggered a compensatory NLRP1 inflammasome that accelerated aging — so blanket inflammasome suppression is not assumed beneficial. There is no approved NLRP3 inhibitor; candidates exist only inside registered trials. Educational information, not medical advice.

    Phase 3 RCT · n=10,061 post-MI, hsCRP ≥2 mg/L · NEJM 2017

    Canakinumab lowered hsCRP by dose — but only 150 mg cut cardiac events

    Source: Ridker et al., CANTOS, New England Journal of Medicine, 2017 (n=10,061 post-myocardial-infarction patients with hsCRP ≥2 mg/L). Canakinumab, a monoclonal antibody against IL-1β — the cytokine released downstream of NLRP3 — reduced hsCRP dose-dependently, yet only the 150 mg dose significantly lowered major cardiovascular events (HR 0.85; about 15%; p=0.021); the 50 mg and 300 mg doses did not meet the prespecified threshold, and fatal infections rose. Oral NLRP3 inhibitors such as BGE-102 (Phase 2 QUELL-CV; topline expected Q4 2026) target this same axis more proximally. This illustrates that lowering inflammatory markers is necessary but not sufficient. Educational information, not medical advice.

    Key references: BioAge Labs Q3 2026 update — BGE-102 / QUELL-CV (company-reported, 2026) · QUELL-CV Phase 2 first participant dosed — BioAge Labs (2026) · Canakinumab anti-inflammatory therapy (CANTOS) — N. Engl. J. Med. (2017) · NLRP3 haploinsufficiency, NLRP1 compensation & accelerated aging — Sci. Adv. (2026)

    Interactions & Precautions

    Contraindications

    • Not for clinical use outside a registered trial
    • Active or recurrent serious infection would be an anticipated exclusion given the class blocks innate immune signalling
    • Immunosuppression

    Potential Risks

    • •No published efficacy or safety dataset for any oral NLRP3 inhibitor in aging
    • •hsCRP is a surrogate endpoint - CANTOS is the cautionary reminder that inflammation reduction buys events but also costs fatal infections
    • •Sponsor framing of Phase 1 results is not peer-reviewed

    Potential Side Effects

    Unknown for oral NLRP3 inhibitors
    Class-anticipated: increased infection risk from blunting IL-1-beta signalling, as observed with canakinumab in CANTOS
    Hepatic enzyme elevation reported for some inflammasome-targeting programmes

    Practitioner Notes

    Clinical annotations from Dr. Goel

    This is the inflammaging class most likely to produce interpretable human data in the next 12 months, so it is worth understanding now - but there is nothing to prescribe. Two practical points. First, when patients ask about "lowering inflammation for longevity," the honest framing is that the only inflammation-lowering agents with hard cardiovascular outcome data are colchicine and canakinumab, both with real trade-offs, and that hsCRP reduction alone has never been shown sufficient. Second, hold sponsor claims at arm's length: "potentially best-in-class hsCRP reduction" is a press-release phrase, and topline Phase 2 data guided for H2 2026 will be the first meaningful read. Separately, the TNFR1/intestinal stem cell work (Nature Aging, August 2026) is worth knowing because patients on TNF inhibitors for rheumatologic disease will increasingly ask whether they are getting an anti-aging benefit - the answer is that this is murine, mechanistic, and no aging-indication human data exist. Updated November 5, 2026: The near-term, decision-relevant read is QUELL-CV topline (oral NLRP3 inhibitor BGE-102), guided for Q4 2026; Phase 2 is now fully enrolled (~160) with an hsCRP primary endpoint. Keep framing the striking Phase 1 numbers (up to 98% IL-1-beta and about 86% hsCRP suppression) as company-reported and surrogate - absorption and target engagement, not proven benefit - and remember the CANTOS lesson that even validated hsCRP/IL-1-beta lowering cut cardiovascular events at only one dose and raised fatal infections. The 2026 Science Advances NLRP1/NLRP3 work is worth citing when patients assume blanket inflammasome suppression is anti-aging: in mice, partial genetic loss of NLRP3 accelerated aging via compensatory NLRP1. Nothing here changes practice today - there is still no NLRP3 inhibitor to prescribe outside a trial.
    SG

    Dr. Sanjeev Goel

    Chief Medical Officer, Peak Human

    Cost & Access

    Cost Range

    Not commercially available

    Accessibility

    Clinical trials only

    Availability varies by location

    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation